Intellia Therapeutics, Inc. (NTLA) stock
NTLANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 3/3025% above fair value
$9.70−0.85 (-8.06%)
Close on Nov 13, 2026Market cap $1.36BP/E –Yield –
Intellia Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Intellia Therapeutics's enterprise value was $1.16B on Nov 11, 2026, against $529.88M a year earlier. Over the last 5 years it ranged from $123.92M to $7.99B, with a median of $1.36B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $1.16B | +118.9% |
| 2025 | Dec 31, 2025 | $529.88M | +0.2% |
| 2024 | Dec 31, 2024 | $528.83M | -71.6% |
| 2023 | Dec 29, 2023 | $1.86B | +1.0% |
| 2022 | Dec 30, 2022 | $1.84B | -76.9% |
| 2021 | Dec 31, 2021 | $7.99B | +186.4% |
| 2020 | Dec 31, 2020 | $2.79B | +547.3% |
| 2019 | Dec 31, 2019 | $431.11M | +44.3% |
| 2018 | Dec 31, 2018 | $298.74M | -36.6% |
| 2017 | Dec 29, 2017 | $471.29M | +160.0% |
| 2016 | Dec 30, 2016 | $181.28M | – |
See a number that looks wrong?